Die OtherLevels Holdings Ltd Aktie wird unter der ISIN AUOLV7 an der Börse Frankfurt gehandelt. OtherLevels Holdings Ltd ist ein Unternehmen aus. Finden Sie heraus, wer die direkten Inhaber, institutionellen Inhaber und Investmentfondsinhaber für OTHERLEVELS HLDGS LTD (7OL.F) sind. Name, OtherLevels Holdings Ltd. Kurzname, OtherLevels. Namenszusatz, Registered Shs. Kategorie, Aktien. Aktientyp, Stammaktien. WKN, A14PX7.
Aktueller Chart OTHERLEVELS AktieName, OtherLevels Holdings Ltd. Kurzname, OtherLevels. Namenszusatz, Registered Shs. Kategorie, Aktien. Aktientyp, Stammaktien. WKN, A14PX7. Name, Symbol, Markt, Aktientyp, ISIN, Beschreibung. OtherLevels Holdings Limited, OLV, Australische Börse, Ordinary Share, AUOLV7. OtherLevels Holdings Limited (7OL.F). Zur Watchlist hinzufügen. Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR. 0, 0, (0,00%). Ab 7. August.
Otherlevels Holdings Limited VideoOpen Your Heart, Heal Your Back • LYT™ YOGA FLOW
вBislang sind wir Otherlevels Holdings Limited einem blauen Auge Otherlevels Holdings Limited gekommen. - Bestbewertete Nachrichten OTHERLEVELS HOLDINGS LIMITEDDeutsche Bank. OTHERLEVELS HOLDINGS LIMITED: News, information and stories for OTHERLEVELS HOLDINGS LIMITED | Australian Stock Exchange: OLV | Australian Stock Exchange. OTHERLEVELS HOLDINGS LIMITED: Financial news and information Stock OTHERLEVELS HOLDINGS LIMITED | Australian Stock Exchange: OLV | Australian Stock Exchange. OTHERLEVELS HOLDINGS LIMITED ACN Annual Report For the year ended 30 June Phone: 07 | the-only-backpackers-inn.com OtherLevels Holding Limited Edward Street, Australia. Art ALLE Tauchende VГ¶gel Bärisch. Diskussionen Aktuelle Einschätzungen Mitglieder Rangliste. Nachrichten Nachrichten Nachrichten auf FN.
Fundamental Rankings. Stock Screener Home. MarketScreener tools. Dynamic chart. Our Services. MarketScreener Portfolios.
Add to my list. Upcoming sector events. More events. All rights reserved. Log in E-mail. Engage smarter. Retain longer. Reduce acquisition costs, drive retention and increase revenue, with relevant, intelligent messaging.
Find out more. But on the other hand, the company made a loss during the last year, which makes us a little cautious.
Given that insiders also own a fair bit of OtherLevels Holdings we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.
For example, OtherLevels Holdings has 4 warning signs and 2 which can't be ignored we think you should know about.
Of course OtherLevels Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body.
We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team simplywallst. This article by Simply Wall St is general in nature.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.
Simply Wall St has no position in the stocks mentioned. We aim to bring you long-term focused research analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
A new year, a new addition to the stock portfolio — what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom.
But the markets are up. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That's where the Wall Street pros can lend a hand.
Not to mention each has earned a Moderate or Strong Buy consensus rating. Esperion ESPR We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels — a major factor contributing to heart disease.
In February , both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.
The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14, patients with top-line data expected in the second half of The study covers 1, locations in 32 countries around the world.
Listed company. Sector News. All Analysis. Stock Picks. All stock picks. My Portfolio. My Watchlists. Investment themes.
Top News. Top Fundamentals. Top Technicals. Top Movers. Top Fundamentals. Top Technicals. Top Movers. Investment selections.
Technical Rankings. Fundamental Rankings. Stock Screener Home. MarketScreener tools. Dynamic chart. Our Services. MarketScreener Portfolios.